(10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(thiophen-2-yl)-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-trien-12-one

• ChemBase ID: 72802
• Molecular Formular: C32H32O13S
• Molecular Mass: 656.65368
• Monoisotopic Mass: 656.15636208
• SMILES: c1c2c(cc3c1OCO3)[C@H]([C@@H]1[C@@H]([C@@H]2O[C@H]2[C@@H]([C@H]([C@H]3[C@H](O2)CO[C@H](O3)c2cccs2)O)O)COC1=O)c1cc(c(c(c1)OC)O)OC
• Canonical SMILES: COc1cc(cc(c1O)OC)[C@H]1[C@H]2C(=O)OC[C@@H]2[C@@H](c2c1cc1OCOc1c2)O[C@@H]1O[C@@H]2CO[C@H](O[C@H]2[C@@H]([C@H]1O)O)c1cccs1
• InChI: InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
• InChIKey: NRUKOCRGYNPUPR-QBPJDGROSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(thiophen-2-yl)-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-trien-12-one
• IUPAC Traditional name: vehem
• Synonyms: Vumon; VM-26; Vehem; NSC 122819; Teniposide

Database IDs

• CAS Number: 29767-20-2
• PubChem SID: 162037723
• PubChem CID: 452548

CALCULATED PROPERTIES

• Acid pKa: 9.329948
• H Acceptors: 12
• H Donor: 3
• LogD (pH = 5.5): 2.7839653
• LogD (pH = 7.4): 2.7789927
• Log P: 2.7840292
• Molar Refractivity: 155.6095 cm^3
• Polarizability: 62.344456 Å^3
• Polar Surface Area: 160.83 Å^2
• Rotatable Bonds: 6
• Lipinski's Rule of Five: false

PROPERTIES

Safety Information

• Storage Condition: -20°C

Product Information

• Salt Data: Free Base

DETAILS

Selleck Chemicals - S1787

Research Area: Cancer
Biological Activity:
Teniposide(Vumon) is a chemotherapeutic medication mainly used in the treatment of childhood acute lymphocytic leukemia (ALL). It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body. Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA-protein cross-links. The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA. [1]

REFERENCES

• http://en.wikipedia.org/wiki/Teniposide